Is Margetuximab included in medical insurance?

Margetuximab is an Fc-engineered monoclonal antibody targeting HER2-positive tumors. It is mainly used to treat patients with metastatic breast cancer who have received multiple lines of anti-HER2 therapy but whose disease has progressed. Compared with the classic trastuzumab, margetuximab has been optimized in the Fc fragment, which can bind to immune effector cells more effectively, enhance antibody-dependent cell-mediated cytotoxicity (ADCC), and thus improve the elimination of tumor cells. This structural modification does not change the target of the antibody, but optimizes its immune activity, so that it may bring additional benefits in some patients who are resistant or have poor response to trastuzumab.

Currently, the drug has been approved for marketing in China and is mainly suitable for the late-line treatment of HER2-positive metastatic breast cancer. In clinical practice, margetuximab is often used in combination with chemotherapy drugs to improve treatment response and delay disease progression. Both overseas and domestic marketing instructions emphasize that patients need to undergo regular monitoring under the guidance of a doctor when using this drug, including cardiac function assessment and adverse reaction management. Although the drug has been approved for marketing in China, due to its short time on the market, its specific price has not been fully disclosed, and it has not yet been included in the national medical insurance directory, which means that patients need to pay for treatment themselves or through specific hospital payment channels. When planning a treatment plan, patients should combine doctor evaluation, hospital policies and their own financial situation to formulate the optimal treatment strategy.

To sum up, margituximab has been marketed as an original drug in China for patients with metastatic breast cancer who have progressed after multi-line anti- HER2 treatment. However, it is not yet included in medical insurance, and the price and accessibility still need to be further clarified.

Reference materials:https://www.margenza.com/